{"id":"gnrh-agonist-antagonist","safety":{"commonSideEffects":[{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Sexual dysfunction"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Bone density loss (with long-term use)"}]},"_chembl":{"chemblId":"CHEMBL442806","moleculeType":"Small molecule","molecularWeight":"1300.49"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"GnRH agonists initially stimulate the pituitary gland before causing desensitization, leading to decreased luteinizing hormone and follicle-stimulating hormone, which reduces testosterone and estrogen production. GnRH antagonists directly block GnRH receptors to immediately suppress gonadotropin release. Both approaches are used in prostate cancer, breast cancer, and to mitigate hot flashes and sexual dysfunction caused by cancer therapies.","oneSentence":"GnRH agonists/antagonists suppress gonadotropin-releasing hormone signaling to reduce sex hormone production, used in oncology to manage hormone-sensitive cancers and their treatment side effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:31:22.879Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prostate cancer (hormone-sensitive)"},{"name":"Breast cancer (hormone-sensitive)"},{"name":"Cancer treatment-related hot flashes and sexual dysfunction"}]},"trialDetails":[{"nctId":"NCT04705038","phase":"NA","title":"Effect of Education on Treatment Decision Making for Patients With Prostate Cancer on Chronic Hormone Treatments","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2020-12-18","conditions":"Prostate Cancer","enrollment":101},{"nctId":"NCT03436654","phase":"PHASE2","title":"Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-06-21","conditions":"Prostate Cancer","enrollment":102},{"nctId":"NCT04191096","phase":"PHASE3","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-12","conditions":"Metastatic Hormone-Sensitive Prostate Cancer","enrollment":1251},{"nctId":"NCT02489318","phase":"PHASE3","title":"A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2015-11-27","conditions":"Prostate Cancer","enrollment":1052},{"nctId":"NCT03767244","phase":"PHASE3","title":"A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-06-11","conditions":"Prostatic Neoplasms","enrollment":2517},{"nctId":"NCT07027124","phase":"PHASE2","title":"Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2026-03-19","conditions":"Prostate Cancer, High-risk Prostate Cancer","enrollment":40},{"nctId":"NCT02871167","phase":"NA","title":"Risk of Infertility Related to Adjuvant Chemotherapy for Early Breast Cancer: Oocyte/Embryo Cryopreservation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Oscar Lambret","startDate":"2016-12","conditions":"Breast Cancer","enrollment":140},{"nctId":"NCT07477626","phase":"PHASE3","title":"Radiotherapy After Prostatectomy for Node Positive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-01-06","conditions":"Prostate Cancer (Post Prostatectomy), Radiotherapy; Image-Guided, Prostate Cancer Non-Metastatic","enrollment":374},{"nctId":"NCT03419234","phase":"PHASE2","title":"Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2018-04-26","conditions":"Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue","enrollment":223},{"nctId":"NCT07466498","phase":"PHASE2","title":"Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial","status":"NOT_YET_RECRUITING","sponsor":"University of Washington","startDate":"2026-08-01","conditions":"Castration-Sensitive Prostate Adenocarcinoma, Metastatic Castration-Sensitive Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":60},{"nctId":"NCT07142551","phase":"PHASE2","title":"Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-03-09","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":60},{"nctId":"NCT07182279","phase":"PHASE1, PHASE2","title":"Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2025-08-01","conditions":"Prostate Cancer (Adenocarcinoma)","enrollment":29},{"nctId":"NCT00936390","phase":"PHASE3","title":"Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2009-09","conditions":"Prostate Cancer","enrollment":1538},{"nctId":"NCT04748042","phase":"PHASE2","title":"Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2021-05-28","conditions":"Prostate Cancer, Castrate Sensitive Prostate Cancer, Oligometastatic Disease","enrollment":21},{"nctId":"NCT05999968","phase":"PHASE1","title":"Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2024-01-12","conditions":"Prostatic Neoplasms","enrollment":10},{"nctId":"NCT05726292","phase":"PHASE2","title":"A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-01-06","conditions":"Prostate Cancer, Prostate Adenocarcinoma","enrollment":90},{"nctId":"NCT05617885","phase":"PHASE1","title":"Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Praful Ravi, MB BCHir, MRCP","startDate":"2023-08-09","conditions":"Metastatic Prostate Cancer, Non-metastatic Prostate Cancer, Prostate Cancer","enrollment":9},{"nctId":"NCT03016741","phase":"PHASE4","title":"Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwestern University","startDate":"2017-03-31","conditions":"Castration-Resistant Prostatic Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma","enrollment":100},{"nctId":"NCT04983095","phase":"NA","title":"Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"Karin Soderkvist","startDate":"2021-10-27","conditions":"Prostate Cancer Metastatic, Radiation Therapy, Positron-Emission Tomography","enrollment":118},{"nctId":"NCT05059236","phase":"PHASE2","title":"A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2021-11-04","conditions":"Metastatic Hormone-sensitive Prostate Cancer","enrollment":223},{"nctId":"NCT04076059","phase":"PHASE3","title":"An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma China, Inc.","startDate":"2019-09-11","conditions":"Metastatic Hormone Sensitive Prostate Cancer","enrollment":180},{"nctId":"NCT07389187","phase":"EARLY_PHASE1","title":"Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2026-02","conditions":"mCRPC","enrollment":10},{"nctId":"NCT05568550","phase":"PHASE2","title":"Pembro With Radiation With or Without Olaparib","status":"RECRUITING","sponsor":"Zin W Myint","startDate":"2023-07-27","conditions":"Prostate Cancer","enrollment":64},{"nctId":"NCT07242534","phase":"PHASE4","title":"Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization.","status":"RECRUITING","sponsor":"Fundacion Dexeus","startDate":"2026-01-19","conditions":"Infertility, Obesity","enrollment":62},{"nctId":"NCT06059118","phase":"PHASE2","title":"Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2023-10-04","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT02949284","phase":"PHASE2","title":"Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2017-06-20","conditions":"Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma","enrollment":90},{"nctId":"NCT07313241","phase":"PHASE2","title":"Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2025-11-14","conditions":"Prostate Cancer","enrollment":68},{"nctId":"NCT05746806","phase":"NA","title":"Trial of Ultrahypofractionated Focal Salvage Radiotherapy for Isolated Prostate Bed Recurrence After Radical Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-03-29","conditions":"Recurrent Prostate Cancer","enrollment":36},{"nctId":"NCT07294027","phase":"NA","title":"ICSI Versus Conventional IVF in Couples With Unexplained Infertility","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-01-01","conditions":"Unexplained Infertility","enrollment":848},{"nctId":"NCT00309985","phase":"PHASE3","title":"Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2006-09-26","conditions":"Metastatic Hormone-sensitive Prostate Cancer","enrollment":790},{"nctId":"NCT06106919","phase":"","title":"Ovarian Blockade During Fertility Preservation in Patients With Endometriosis","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2023-12-18","conditions":"Endometriosis","enrollment":130},{"nctId":"NCT02799602","phase":"PHASE3","title":"Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-11-30","conditions":"Metastatic Hormone-sensitive Prostate Cancer","enrollment":1306},{"nctId":"NCT07164794","phase":"PHASE2","title":"Memantine Hydrochloride in Prostate Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Bin Xu","startDate":"2025-11","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostate Cancer, Neuroendocrine Prostate Cancer (NEPC)","enrollment":15},{"nctId":"NCT03541850","phase":"PHASE2","title":"Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2019-01-29","conditions":"PSA Level Greater Than 0.03, PSA Progression, Stage I Prostate Adenocarcinoma AJCC (American Joint Committee on Cancer ) v7","enrollment":92},{"nctId":"NCT05628363","phase":"NA","title":"Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2023-01-18","conditions":"Prostate Cancer, Cancer of the Prostate","enrollment":28},{"nctId":"NCT02677896","phase":"PHASE3","title":"A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2016-03-09","conditions":"Metastatic Hormone Sensitive Prostate Cancer","enrollment":1150},{"nctId":"NCT06060587","phase":"PHASE2","title":"Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2023-10-19","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT06392841","phase":"PHASE2","title":"Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations","status":"WITHDRAWN","sponsor":"Qian Qin","startDate":"2025-10","conditions":"Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Deleterious HRR Gene Mutation, BRCA1 Gene Mutation","enrollment":""},{"nctId":"NCT04787744","phase":"PHASE2, PHASE3","title":"Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2021-07-01","conditions":"Prostate Cancer, Oligometastasis, Oligorecurrence","enrollment":464},{"nctId":"NCT06877429","phase":"","title":"Is the Diurnal Variation in Circulating Levels of Cortisol Reflected in Follicular Fluid of Preovulatory Follicles Close to Ovulation?","status":"NOT_YET_RECRUITING","sponsor":"ART Fertility Clinics LLC","startDate":"2025-12-30","conditions":"Healthy","enrollment":20},{"nctId":"NCT05346848","phase":"PHASE2","title":"Randomized Phase II Trial on Short Term Darolutamide Concomitant to Radiation Therapy for Patients With Intermediate Unfavorable Risk Prostate Cancer","status":"RECRUITING","sponsor":"Institut Bergonié","startDate":"2023-02-24","conditions":"Prostate Cancer","enrollment":62},{"nctId":"NCT04934722","phase":"PHASE3","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-05-25","conditions":"Metastatic Hormone-Sensitive Prostate Cancer","enrollment":186},{"nctId":"NCT07171970","phase":"NA","title":"IVM - Fresh ET (THE SAIGON PROTOCOL) Versus IVF - FET in PCOS Women","status":"RECRUITING","sponsor":"Mỹ Đức Hospital","startDate":"2025-09-22","conditions":"Polycystic Ovary Syndrome (PCOS), In Vitro Maturation of Oocytes, Fresh Embryo Transfer","enrollment":600},{"nctId":"NCT06528210","phase":"PHASE2","title":"Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer","status":"WITHDRAWN","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-04-16","conditions":"High Risk Prostate Carcinoma, Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8","enrollment":""},{"nctId":"NCT05974774","phase":"PHASE3","title":"Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors","status":"RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2025-05-23","conditions":"Prostate Cancer","enrollment":1600},{"nctId":"NCT02972060","phase":"PHASE2","title":"ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2017-12-01","conditions":"Prostate Cancer","enrollment":61},{"nctId":"NCT06922318","phase":"PHASE2","title":"The COSMYC Trial (COmbined Suppression of MYC)","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2025-08-19","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":50},{"nctId":"NCT06390904","phase":"PHASE2, PHASE3","title":"GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xiaojun Chen","startDate":"2022-07-13","conditions":"Atypical Endometrial Hyperplasia, Progesterone Resistance, Obesity","enrollment":29},{"nctId":"NCT06379113","phase":"PHASE2, PHASE3","title":"GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients","status":"RECRUITING","sponsor":"Xiaojun Chen","startDate":"2022-07-13","conditions":"Endometrial Neoplasms, Atypical Endometrial Hyperplasia, Progesterone Resistance","enrollment":29},{"nctId":"NCT05765500","phase":"PHASE2","title":"RecoverPC: Relugolix vs GnRH Agonist in Quality of Life","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-02-12","conditions":"Prostate Cancer, Prostatic Neoplasms","enrollment":110},{"nctId":"NCT06280677","phase":"","title":"Aurora Test for ART Donor Patients (AURORA-Donor)","status":"RECRUITING","sponsor":"Fertiga, Belgium","startDate":"2024-02-16","conditions":"Infertility","enrollment":160},{"nctId":"NCT01952223","phase":"PHASE3","title":"A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2013-12","conditions":"Adenocarcinoma of Prostate, Progression of Prostate Cancer","enrollment":761},{"nctId":"NCT05448547","phase":"PHASE3","title":"Immediate Curative vs Conservative Treatment in Older Men With M0, High-risk Prostate Cancer","status":"RECRUITING","sponsor":"Sven Löffeler","startDate":"2022-11-04","conditions":"Prostate Cancer","enrollment":980},{"nctId":"NCT06312670","phase":"PHASE2","title":"Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Pedro Barata, MD, MSc","startDate":"2024-05-16","conditions":"Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Prostate Cancer, Prostate Adenocarcinoma","enrollment":13},{"nctId":"NCT03703778","phase":"","title":"Real-life Evaluation of the Effect of ADT in Prostate Cancer Patients in Asia (READT Asia Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2016-05-22","conditions":"Prostate Cancer","enrollment":300},{"nctId":"NCT04743934","phase":"PHASE2","title":"Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Andrew McDonald","startDate":"2021-07-02","conditions":"Prostate Adenocarcinoma","enrollment":44},{"nctId":"NCT03641560","phase":"PHASE4","title":"A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2018-09-19","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":52},{"nctId":"NCT02496754","phase":"NA","title":"Follicular Long GnRH Agonist Versus Antagonist Protocol in PCOS Women Undergoing in Vitro Fertilization","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2016-06","conditions":"Clinical Pregnancy Rate, Ovulation Induction, IVF","enrollment":1266},{"nctId":"NCT06812559","phase":"","title":"Progesterone Primed Ovarian Stimulation Versus GnRH Antagonist Protocols in Women With Polycystic Ovarian Syndrome","status":"COMPLETED","sponsor":"El Shatby University Hospital for Obstetrics and Gynecology","startDate":"2023-12-01","conditions":"Controlled Ovarian Hyperstimulation, Polycystic Ovarian Syndrome","enrollment":100},{"nctId":"NCT06838520","phase":"","title":"Effect of ADT and ARPI on Bone Loss of Patients with Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-04-01","conditions":"Prostate Cancer (Adenocarcinoma)","enrollment":200},{"nctId":"NCT04289805","phase":"PHASE4","title":"Controlled Ovarian Stimulation in Newly Diagnosed Breast Cancer PatiEnts (fAMHOPE)","status":"TERMINATED","sponsor":"Erasme University Hospital","startDate":"2019-02-25","conditions":"Breast Neoplasm Malignant Female","enrollment":96},{"nctId":"NCT05286554","phase":"PHASE4","title":"Addition of Gonadotropin Releasing Hormone Agonist to Luteal Phase Support","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2022-03-17","conditions":"Female Infertility","enrollment":75},{"nctId":"NCT05330130","phase":"PHASE1","title":"Impact of FSH Dosage During Ovarian Stimulation for IVF/ICSI in Granulosa Cells","status":"COMPLETED","sponsor":"ART Fertility Clinics LLC","startDate":"2023-07-05","conditions":"Ovarian Function Insufficiency, Fertility Issues, Infertility,Female","enrollment":6},{"nctId":"NCT03569241","phase":"PHASE2","title":"PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2018-04-27","conditions":"Prostate Cancer, Prostate Cancer Metastatic, Metastatic Cancer","enrollment":196},{"nctId":"NCT02918968","phase":"PHASE4","title":"Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2016-11-02","conditions":"Prostate Cancer","enrollment":206},{"nctId":"NCT01957436","phase":"PHASE3","title":"A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2013-11-13","conditions":"Metastatic Prostate Cancer","enrollment":1173},{"nctId":"NCT02799706","phase":"PHASE3","title":"Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2017-09-25","conditions":"Prostate Cancer","enrollment":885},{"nctId":"NCT06655259","phase":"PHASE2","title":"Combination of TURP and Standard Systemic Therapy for MPCa","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-09-21","conditions":"Metastatic Prostate Cancer","enrollment":200},{"nctId":"NCT03777982","phase":"PHASE3","title":"Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-04-20","conditions":"Prostate Cancer","enrollment":12},{"nctId":"NCT03809429","phase":"PHASE3","title":"Follitropin Delta in Long GnRH Agonist and GnRH Antagonist Protocols (BEYOND)","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2019-04-29","conditions":"Infertility, Female","enrollment":437},{"nctId":"NCT04721522","phase":"","title":"The Impact of Endometrial Compaction on Assisted Reproductive Technology Outcome","status":"RECRUITING","sponsor":"Zagazig University","startDate":"2021-01-29","conditions":"Embryo Implantation, ART","enrollment":356},{"nctId":"NCT03311555","phase":"PHASE2","title":"A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)","status":"COMPLETED","sponsor":"Andrew J. Armstrong, MD","startDate":"2018-03-28","conditions":"Prostate Cancer","enrollment":39},{"nctId":"NCT04989348","phase":"NA","title":"Euploid Rate of Blastocyst Derived From PPOS VS Antagonist Protocol","status":"COMPLETED","sponsor":"Shanghai First Maternity and Infant Hospital","startDate":"2021-08-04","conditions":"IVF","enrollment":240},{"nctId":"NCT02995330","phase":"PHASE1","title":"Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2017-02-09","conditions":"Prostate Cancer","enrollment":3},{"nctId":"NCT03899077","phase":"PHASE2","title":"Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP","status":"UNKNOWN","sponsor":"Cancer Research Antwerp","startDate":"2019-04-05","conditions":"Cancer of Prostate","enrollment":202},{"nctId":"NCT06199960","phase":"PHASE3","title":"Dual Ovarian Stimulation (Duostim) and Shanghai Protocols in Poor Ovarian Responders","status":"COMPLETED","sponsor":"Royan Institute","startDate":"2019-08-02","conditions":"Assisted Reproductive Techniques","enrollment":116},{"nctId":"NCT02312089","phase":"PHASE4","title":"GnRHa for Luteal Phase Support in GnRH Antagonist Protocol Cycles","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2016-08-07","conditions":"Infertility","enrollment":200},{"nctId":"NCT04724486","phase":"PHASE4","title":"Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology During IVF/ICSI","status":"COMPLETED","sponsor":"Damascus University","startDate":"2020-08-22","conditions":"In Vitro Fertilization, Intracytoplasmic Sperm Injection, Infertility","enrollment":50},{"nctId":"NCT04724343","phase":"PHASE4","title":"Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes.","status":"COMPLETED","sponsor":"Damascus University","startDate":"2019-12-22","conditions":"In Vitro Fertilization, Intracytoplasmic Sperm Injection, Infertility","enrollment":50},{"nctId":"NCT04727684","phase":"PHASE4","title":"Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology in Polycystic Ovary Syndrome Patients During IVF/ICSI","status":"COMPLETED","sponsor":"Damascus University","startDate":"2020-08-22","conditions":"In Vitro Fertilization, Infertility, Intracytoplasmic Sperm Injection","enrollment":50},{"nctId":"NCT04727671","phase":"PHASE4","title":"Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes in Polycystic Ovary Syndrome Patients.","status":"COMPLETED","sponsor":"Damascus University","startDate":"2019-12-22","conditions":"In Vitro Fertilization, Intracytoplasmic Sperm Injection, Infertility","enrollment":50},{"nctId":"NCT04447872","phase":"NA","title":"The LUTEAL Trial: Luteal Stimulation vs. Estrogen Priming Protocol","status":"UNKNOWN","sponsor":"Northwell Health","startDate":"2020-09-15","conditions":"Infertility, Diminished Ovarian Reserve, IVF","enrollment":142},{"nctId":"NCT05972902","phase":"PHASE3","title":"Dydrogesterone, Cetrorelix Acetate and Triptorelin in Intra Cytoplasmic Sperm Injection Outcomes","status":"UNKNOWN","sponsor":"Beni-Suef University","startDate":"2023-07-15","conditions":"IVF","enrollment":387},{"nctId":"NCT03298633","phase":"NA","title":"ICSI Versus Conventional IVF in Couples With Non-severe Male Infertility","status":"COMPLETED","sponsor":"Jie Qiao","startDate":"2018-04-04","conditions":"Male Infertility","enrollment":2387},{"nctId":"NCT04157725","phase":"PHASE4","title":"Mild Stimulation Protocol Using Clomiphene Citrate for Women With PCOS Undergoing in Vitro Fertilization","status":"UNKNOWN","sponsor":"American University of Beirut Medical Center","startDate":"2023-06-01","conditions":"PCO - Polycystic Ovaries, Infertility","enrollment":154},{"nctId":"NCT05937490","phase":"PHASE4","title":"Adenomyosis and ART","status":"UNKNOWN","sponsor":"Azienda Ospedaliero-Universitaria di Modena","startDate":"2023-03-27","conditions":"Adenomyosis","enrollment":500},{"nctId":"NCT03940235","phase":"PHASE2","title":"Radioablation With or Without Androgen DeprIvation Therapy in Metachronous Prostate Cancer OligometaStAsis","status":"UNKNOWN","sponsor":"European Institute of Oncology","startDate":"2019-10-01","conditions":"Oligometastatic Prostate Cancer","enrollment":150},{"nctId":"NCT04549649","phase":"NA","title":"The Effect of Dual Trigger for Final Oocyte Maturation on IVF/ICSI Outcomes in Patients With Suboptimal Ovarian Response","status":"COMPLETED","sponsor":"Royan Institute","startDate":"2019-11-01","conditions":"Ovarian Stimulation, Reproductive Techniques, Assisted","enrollment":52},{"nctId":"NCT04586686","phase":"NA","title":"Combining Interventions of Fertility Preservation to Mitigate Fertility Loss After Breast Cancer","status":"UNKNOWN","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2022-11-01","conditions":"Breast Cancer Female","enrollment":41},{"nctId":"NCT04616729","phase":"PHASE1, PHASE2","title":"DEPO-Trigger Trial: GnRH Agonist DEPOt TRIGGER for Final Oocyte Maturation","status":"UNKNOWN","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2022-11-01","conditions":"Breast Cancer Female","enrollment":30},{"nctId":"NCT04446845","phase":"PHASE4","title":"Double Stimulation Followed by a Fresh Embryo Transfer","status":"COMPLETED","sponsor":"Fundación Santiago Dexeus Font","startDate":"2020-10-30","conditions":"Infertility","enrollment":120},{"nctId":"NCT04071574","phase":"PHASE1, PHASE2","title":"Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility","status":"COMPLETED","sponsor":"Lebanese University","startDate":"2018-02-01","conditions":"Female Infertility, Female Infertility Due to Ovulatory Disorder, Premature Ovarian Failure","enrollment":200},{"nctId":"NCT04600986","phase":"NA","title":"Repeated Doses of GnRH Agonist as Oocyte Triggering in Antagonist Protocol for Patients With Polycystic Ovary Syndrome","status":"COMPLETED","sponsor":"Royan Institute","startDate":"2020-05-30","conditions":"Polycystic Ovary Syndrome","enrollment":70},{"nctId":"NCT05713578","phase":"EARLY_PHASE1","title":"Efficacy and Safety of Apantamide Combined With Docetaxel and ADT vs. Apantamide Combined With ADT in Patients With High Tumor Burden mHSPC: a Multicenter and Prospective Cohort Study","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2023-03-01","conditions":"Cohort Studies","enrollment":220},{"nctId":"NCT04168892","phase":"","title":"Anti-Müllerian Hormone (AMH) Measured With Fully Automated Assay Versus AFC in the Prediction of Ovarian Response","status":"COMPLETED","sponsor":"Andros Day Surgery Clinic","startDate":"2019-09-20","conditions":"Ovarian Response","enrollment":160},{"nctId":"NCT05358678","phase":"","title":"Cesarean Section Scar Niche: The Impact on ART Outcome","status":"UNKNOWN","sponsor":"Rahem Fertility Center","startDate":"2022-05-25","conditions":"Cesarean Section, ART","enrollment":266},{"nctId":"NCT03349905","phase":"NA","title":"Deferred Versus Fresh Embryo Transfers","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-09-24","conditions":"Infertility, Female","enrollment":237},{"nctId":"NCT02582749","phase":"PHASE2","title":"Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases","status":"TERMINATED","sponsor":"Ajjai Alva, MD","startDate":"2016-04","conditions":"Prostate Cancer, Bone Metastases, Prostate Neoplasms","enrollment":16},{"nctId":"NCT02663908","phase":"PHASE3","title":"A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease","status":"TERMINATED","sponsor":"Ferring Pharmaceuticals","startDate":"2016-04-19","conditions":"Prostate Cancer","enrollment":545},{"nctId":"NCT05422911","phase":"PHASE2","title":"Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.","status":"NOT_YET_RECRUITING","sponsor":"James J. Peters Veterans Affairs Medical Center","startDate":"2022-06-30","conditions":"Metastatic Cancer, Neoplasm, Prostate","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":20,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"GnRH agonist/antagonist","genericName":"GnRH agonist/antagonist","companyName":"Memorial Sloan Kettering Cancer Center","companyId":"memorial-sloan-kettering-cancer-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GnRH agonists/antagonists suppress gonadotropin-releasing hormone signaling to reduce sex hormone production, used in oncology to manage hormone-sensitive cancers and their treatment side effects. Used for Prostate cancer (hormone-sensitive), Breast cancer (hormone-sensitive), Cancer treatment-related hot flashes and sexual dysfunction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}